Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV.

Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3. Epub 2012 Jul 2.

PMID:
22759480
2.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
3.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

4.

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Keisner SV, Shah SR.

Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. Review.

PMID:
21395357
5.

Pazopanib: in advanced renal cell carcinoma.

Sanford M, Keating GM.

BioDrugs. 2010 Oct 1;24(5):279-86. doi: 10.2165/11205480-000000000-00000. Review.

PMID:
20649181
6.

Pazopanib in renal cell carcinoma.

Ward JE, Stadler WM.

Clin Cancer Res. 2010 Dec 15;16(24):5923-7. doi: 10.1158/1078-0432.CCR-10-0728. Epub 2010 Nov 8. Review.

7.

First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.

Schmidinger M, Wittes J.

Curr Opin Urol. 2015 Sep;25(5):395-401. doi: 10.1097/MOU.0000000000000207. Review.

PMID:
26148069
8.

Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

Iacovelli R, Alesini D, Palazzo A, Trenta P, Santoni M, De Marchis L, Cascinu S, Naso G, Cortesi E.

Cancer Treat Rev. 2014 Mar;40(2):271-5. doi: 10.1016/j.ctrv.2013.09.003. Epub 2013 Sep 11. Review.

PMID:
24070900
9.

Pazopanib: a review of its use in the management of advanced renal cell carcinoma.

McCormack PL.

Drugs. 2014 Jul;74(10):1111-25. doi: 10.1007/s40265-014-0243-3. Review.

PMID:
24935162
10.

Pazopanib for the treatment of renal cancer.

Al-Marrawi MY, Rini B.

Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7. Review. Erratum in: Expert Opin Pharmacother. 2011 Jun;12(8):1349.

PMID:
21470066
11.

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.

Dranitsaris G, Schmitz S, Broom RJ.

J Cancer Res Clin Oncol. 2013 Nov;139(11):1917-26. doi: 10.1007/s00432-013-1510-5. Epub 2013 Sep 14. Review.

PMID:
24037486
12.

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.

Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, Mowatt G, Vale L.

Pharmacoeconomics. 2013 Jan;31(1):15-24. doi: 10.1007/s40273-012-0006-5. Review.

PMID:
23329590
13.
14.

Pazopanib for the treatment of renal cell carcinoma and other malignancies.

Sonpavde G, Hutson TE, Sternberg CN.

Drugs Today (Barc). 2009 Sep;45(9):651-61. doi: 1396674/dot.2009.45.9.1414786. Review.

PMID:
19956806
15.

Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.

Larkin J, Paine A, Tumur I, Cappelleri JC, Healey PJ Sr, Foley G, Mitchell S, Kroes M, Chen C.

Expert Opin Pharmacother. 2013 Jan;14(1):27-39. doi: 10.1517/14656566.2013.758713. Epub 2012 Dec 21. Review.

PMID:
23256638
16.

Optimal management of metastatic renal cell carcinoma: current status.

Escudier B, Albiges L, Sonpavde G.

Drugs. 2013 Apr;73(5):427-38. doi: 10.1007/s40265-013-0043-1. Review.

PMID:
23572408
17.

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.

Sonpavde G, Hutson TE, Sternberg CN.

Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253. Review.

PMID:
18230058
18.

Practice and progress in kidney cancer: methodology for novel drug development.

Rini BI, Weinberg V, Small EJ.

J Urol. 2004 Jun;171(6 Pt 1):2115-21. Review.

PMID:
15126769
19.

A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.

Funakoshi T, Lee CH, Hsieh JJ.

Cancer Treat Rev. 2014 May;40(4):533-47. doi: 10.1016/j.ctrv.2013.11.008. Epub 2013 Dec 4. Review.

PMID:
24398141
20.

Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.

Mehta A, Sonpavde G, Escudier B.

Future Oncol. 2014 Aug;10(11):1819-26. doi: 10.2217/fon.14.120. Review.

PMID:
25325825
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk